Header cover image

Australian (ASX) Biotech Industry Analysis

UpdatedJan 24, 2025
DataAggregated Company Financials
Companies32
  • 7D-1.5%
  • 3M-5.0%
  • 1Y-2.0%
  • YTD-3.4%

Over the last 7 days, the Biotech industry has dropped 1.5%, driven by a pullback from CSL of 1.1%. In contrast, Mesoblast has gained 6.7%. Over the last year, the industry has been flat overall. Looking forward, earnings are forecast to grow by 15% annually.

Industry Valuation and Performance

Has the Australian Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Fri, 24 Jan 2025AU$146.8bAU$24.5bAU$3.7b23.8x40x6x
Sun, 22 Dec 2024AU$148.5bAU$24.6bAU$3.7b24.1x40.4x6x
Tue, 19 Nov 2024AU$145.0bAU$23.8bAU$3.5b25.6x40.9x6.1x
Thu, 17 Oct 2024AU$157.6bAU$23.1bAU$3.4b28.2x46.1x6.8x
Sat, 14 Sep 2024AU$156.6bAU$23.0bAU$3.4b29.4x46x6.8x
Mon, 12 Aug 2024AU$159.6bAU$22.4bAU$3.3b31.5x48.5x7.1x
Wed, 10 Jul 2024AU$153.8bAU$21.9bAU$3.2b31.8x48x7x
Fri, 07 Jun 2024AU$150.9bAU$22.2bAU$3.3b31.2x46.4x6.8x
Sun, 05 May 2024AU$143.1bAU$22.2bAU$3.3b30.2x44x6.4x
Tue, 02 Apr 2024AU$147.5bAU$22.5bAU$3.3b30.3x44.7x6.5x
Thu, 29 Feb 2024AU$145.6bAU$22.6bAU$3.4b29.9x43.4x6.5x
Sat, 27 Jan 2024AU$149.0bAU$20.8bAU$2.8b34.1x53.9x7.1x
Mon, 25 Dec 2023AU$143.3bAU$20.2bAU$2.7b34.3x53.8x7.1x
Wed, 22 Nov 2023AU$130.7bAU$20.9bAU$2.8b32x47x6.3x
Fri, 20 Oct 2023AU$120.1bAU$21.7bAU$2.9b29.3x41.3x5.5x
Sun, 17 Sep 2023AU$137.1bAU$21.4bAU$2.8b32.1x49x6.4x
Tue, 15 Aug 2023AU$134.8bAU$18.5bAU$2.4b37.7x56.2x7.3x
Thu, 13 Jul 2023AU$135.8bAU$18.0bAU$2.3b36.5x58.5x7.6x
Sat, 10 Jun 2023AU$155.9bAU$17.9bAU$2.3b40.9x67.4x8.7x
Mon, 08 May 2023AU$154.3bAU$17.8bAU$2.3b41.4x67.3x8.7x
Wed, 05 Apr 2023AU$148.5bAU$17.8bAU$2.3b40.2x64.9x8.3x
Fri, 03 Mar 2023AU$148.9bAU$17.8bAU$2.3b41.1x64.9x8.4x
Sun, 29 Jan 2023AU$150.7bAU$15.2bAU$2.4b55.5x63.1x9.9x
Tue, 27 Dec 2022AU$147.5bAU$16.0bAU$2.6b46.2x57.8x9.2x
Thu, 24 Nov 2022AU$152.2bAU$16.2bAU$2.6b43x58.8x9.4x
Sat, 22 Oct 2022AU$137.0bAU$17.0bAU$2.7b39.3x50.2x8.1x
Mon, 19 Sep 2022AU$145.8bAU$16.0bAU$2.6b45.8x56.9x9.1x
Wed, 17 Aug 2022AU$151.2bAU$15.3bAU$2.8b42.1x54.9x9.9x
Fri, 15 Jul 2022AU$149.9bAU$15.9bAU$2.9b38.4x52.2x9.4x
Sun, 12 Jun 2022AU$136.7bAU$15.3bAU$2.8b34.4x49.5x8.9x
Tue, 10 May 2022AU$136.4bAU$15.1bAU$2.8b35.4x49.4x9x
Thu, 07 Apr 2022AU$136.3bAU$14.1bAU$2.6b39.8x53.4x9.6x
Sat, 05 Mar 2022AU$132.0bAU$14.7bAU$2.7b40.1x49.5x9x
Mon, 31 Jan 2022AU$133.0bAU$15.0bAU$2.9b36.3x46.5x8.9x
Price to Earnings Ratio

46.5x


Total Market Cap: AU$133.0bTotal Earnings: AU$2.9bTotal Revenue: AU$15.0bTotal Market Cap vs Earnings and Revenue0%0%0%
Australian Biotech Industry Price to Earnings3Y Average 51.8x202320242025
Current Industry PE
  • Investors are pessimistic on the Australian Biotechs industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 40.0x which is lower than its 3-year average PE of 51.8x.
  • The 3-year average PS ratio of 7.8x is higher than the industry's current PS ratio of 6.0x.
Past Earnings Growth
  • The earnings for companies in the Biotechs industry have grown 8.7% per year over the last three years.
  • Revenues for these companies have grown 18% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Australian Healthcare industry?

AU Market0.65%
Healthcare0.09%
Biotech-1.53%
Biotech-1.53%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
MSB MesoblastAU$2.876.7%
+AU$490.2m
983.0%PS386.2x
TLX Telix PharmaceuticalsAU$27.533.5%
+AU$314.6m
143.6%PE187.4x
OPT OptheaAU$0.9718.9%
+AU$190.8m
99.0%PS2881.5x
OCC OrthocellAU$1.5916.1%
+AU$52.6m
292.6%PS71.6x
ARX Aroa BiosurgeryAU$0.786.1%
+AU$15.5m
6.8%PS3.9x
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Latest News

MSB

AU$2.87

Mesoblast

7D

6.7%

1Y

983.0%

IMM

AU$0.33

Immutep

7D

1.5%

1Y

-1.5%

ARX

AU$0.78

Aroa Biosurgery

7D

6.1%

1Y

6.8%

TLX

AU$27.53

Telix Pharmaceuticals

7D

3.5%

1Y

143.6%

ATH

AU$0.008

Alterity Therapeutics

7D

-5.9%

1Y

60.0%

OPT

AU$0.97

Opthea

7D

18.9%

1Y

99.0%

RAD

AU$0.027

Radiopharm Theranostics

7D

-3.6%

1Y

-63.0%

DXB

AU$0.45

Dimerix

7D

-16.8%

1Y

161.8%

PAR

AU$0.47

Paradigm Biopharmaceuticals

7D

3.3%

1Y

36.2%

OCC

AU$1.59

Orthocell

7D

16.1%

1Y

292.6%

PYC

AU$1.07

PYC Therapeutics

7D

-8.2%

1Y

26.8%

IMU

AU$0.038

Imugene

7D

-5.0%

1Y

-63.8%

PTX

AU$0.058

Prescient Therapeutics

7D

18.4%

1Y

1.8%

RAC

AU$1.25

Race Oncology

7D

-3.8%

1Y

67.8%

CUV

AU$11.84

Clinuvel Pharmaceuticals

7D

-0.3%

1Y

-24.3%